Pet Valu Holdings Ltd. (TSE: PET - Get Free Report) has received an average rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year

Clermont-Ferrand (France), 2 December 2025 (8:45 AM CET). In line with the commitment signed on November 6, 20251, CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (« Wankai »), a listed subsidiary2 of Zhink Group, the 3rd largest PET producer in China and 4th worldwide, announce the signing of the definitive agreement establishing a strategic partnership for the large-scale deployment of CARBIOS's PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.

MARKHAM, Ontario, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, announced today the acceptance by the Toronto Stock Exchange (the “TSX”) of the Company's notice of intention to renew its normal course issuer bid (the “NCIB”). Pursuant to the NCIB, the Company may purchase for cancellation up to an aggregate of 3,449,181 common shares in the capital of the Company (the “Common Shares”), representing approximately 5% of the Company's issued and outstanding Common Shares. As at November 19, 2025, the Company had 68,983,625 Common Shares issued and outstanding.

Clermont-Ferrand (France), 24 November 2025 (18h30 CET).  CARBIOS (Euronext Growth Paris : ALCRB), announces the signing of two new multi-year commercial agreements with major players in beverage industry, for the supply of recycled PET (r-PET).

Vancouver-based Algernon Health (CSE:AGN, OTCQB:AGNPF) is charting a new course in healthcare, setting its sights on one of the fastest-growing frontiers: neuroimaging for Alzheimer's disease. Once a drug-repurposing company known as Algernon Pharmaceuticals, the firm has pivoted into medtech, unveiling a brain-focused PET scanner and laying the groundwork for a network of dedicated imaging centers across North America.

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

WASHINGTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a business development update, including a supply agreement for the largest quantity of enriched silicon-28 received by the Company to date and a strategic acquisition of a radiopharmacy in the United States to complement and expand the operations of PET Labs Pharmaceuticals (Pty) Ltd (“PET Labs”), the Company's South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.

MARKHAM, Ontario, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, will release its financial results for the third quarter of fiscal 2025 at approximately 6:30am ET on Tuesday, November 4, 2025, followed by a conference call at 8:30am ET.

CARBIOS has reduced its operating expenses and has a strong cash position of €72 million as of June 30, 2025, providing a cash horizon of more than 12 months The Longlaville plant construction project is now supported by: Major progress with public financers ADEME and the Regional Council Clear interest from private investors, conditional upon the pre-sale of a significant portion of the future plant's capacity, which has not yet been achieved Recent regulatory developments that enhance the competitiveness of CARBIOS' technology In this context, the resumption of the Longlaville plant construction project is expected before the end of 2025, subject to securing the necessary funding. The plant would then be commissioned in the second half of 2027.

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis.